SG187997A1 - Composition for lowering blood lipid and elevating high-density lipoprotein and method for manufacturing the same - Google Patents
Composition for lowering blood lipid and elevating high-density lipoprotein and method for manufacturing the same Download PDFInfo
- Publication number
- SG187997A1 SG187997A1 SG2011058302A SG2011058302A SG187997A1 SG 187997 A1 SG187997 A1 SG 187997A1 SG 2011058302 A SG2011058302 A SG 2011058302A SG 2011058302 A SG2011058302 A SG 2011058302A SG 187997 A1 SG187997 A1 SG 187997A1
- Authority
- SG
- Singapore
- Prior art keywords
- composition
- density lipoprotein
- blood lipid
- lowering blood
- ankaflavin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 99
- 150000002632 lipids Chemical class 0.000 title claims abstract description 96
- 210000004369 blood Anatomy 0.000 title claims abstract description 91
- 239000008280 blood Substances 0.000 title claims abstract description 91
- 108010010234 HDL Lipoproteins Proteins 0.000 title claims abstract description 85
- 102000015779 HDL Lipoproteins Human genes 0.000 title claims abstract description 85
- 230000003028 elevating effect Effects 0.000 title claims abstract description 83
- 238000000034 method Methods 0.000 title claims abstract description 82
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 63
- AQTJNEHGKRUSLT-ODTNPMSZSA-N (3s,3ar,9ar)-9a-methyl-3-octanoyl-6-[(e)-prop-1-enyl]-3,3a,4,8-tetrahydrofuro[3,2-g]isochromene-2,9-dione Chemical compound C([C@@H]1[C@H](C(O[C@@]1(C)C1=O)=O)C(=O)CCCCCCC)C2=C1COC(\C=C\C)=C2 AQTJNEHGKRUSLT-ODTNPMSZSA-N 0.000 claims abstract description 104
- ORJQJZWWJUNMQV-UHFFFAOYSA-N ankaflavin Natural products CCCCCCCC(=O)C1C2C=C3C=C(OC=C3C(=O)C2(C)OC1=O)C=CC ORJQJZWWJUNMQV-UHFFFAOYSA-N 0.000 claims abstract description 104
- XXKNHBAFFJINCK-RVEJDSBJSA-N monascin Chemical compound C([C@@H]1[C@H](C(O[C@@]1(C)C1=O)=O)C(=O)CCCCC)C2=C1COC(\C=C\C)=C2 XXKNHBAFFJINCK-RVEJDSBJSA-N 0.000 claims abstract description 104
- GFSMXLMQRWMHON-UHFFFAOYSA-N monascin Natural products CCCCCC(=O)C1C2C=C3C=C(OC=C3C(=O)C2(C)OC1=O)C=CC GFSMXLMQRWMHON-UHFFFAOYSA-N 0.000 claims abstract description 104
- GIKQHOXMDCDAPT-UHFFFAOYSA-N monascusone B Natural products CC=CC1=CC2=C(CO1)C(=O)C3(C)OC(=O)C(C3C2)C(=O)C GIKQHOXMDCDAPT-UHFFFAOYSA-N 0.000 claims abstract description 104
- 241000228347 Monascus <ascomycete fungus> Species 0.000 claims abstract description 54
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 24
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims abstract description 19
- 230000008569 process Effects 0.000 claims abstract description 15
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 15
- 238000004440 column chromatography Methods 0.000 claims abstract description 8
- 238000002953 preparative HPLC Methods 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 62
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 60
- 238000005406 washing Methods 0.000 claims description 45
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 36
- 239000001052 yellow pigment Substances 0.000 claims description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 30
- 239000000741 silica gel Substances 0.000 claims description 30
- 229910002027 silica gel Inorganic materials 0.000 claims description 30
- 239000000049 pigment Substances 0.000 claims description 23
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 47
- 239000000047 product Substances 0.000 description 35
- 230000000694 effects Effects 0.000 description 29
- 235000012000 cholesterol Nutrition 0.000 description 24
- 238000010586 diagram Methods 0.000 description 24
- 108010023302 HDL Cholesterol Proteins 0.000 description 19
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 18
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 18
- 108010028554 LDL Cholesterol Proteins 0.000 description 14
- 244000113306 Monascus purpureus Species 0.000 description 14
- 235000002322 Monascus purpureus Nutrition 0.000 description 14
- 229940057059 monascus purpureus Drugs 0.000 description 14
- 208000024172 Cardiovascular disease Diseases 0.000 description 13
- 201000001320 Atherosclerosis Diseases 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 7
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 229940118019 malondialdehyde Drugs 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 241000209094 Oryza Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229930000044 secondary metabolite Natural products 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- WTEXYKPGDKLLCW-KCSPPWDSSA-N (3Z,9aR)-3-(1-hydroxyhexylidene)-9a-methyl-6-[(E)-prop-1-enyl]furo[3,2-g]isoquinoline-2,9-dione Chemical compound CCCCC\C(O)=C1\C(=O)O[C@]2(C)C1=Cc1cc(\C=C\C)ncc1C2=O WTEXYKPGDKLLCW-KCSPPWDSSA-N 0.000 description 1
- MKDKGLNKTMDNHY-WXUKJITCSA-N (e)-n,5-dihydroxy-n-[3-[5-[3-[hydroxy-[(e)-5-hydroxy-3-methylpent-2-enoyl]amino]propyl]-3,6-dioxopiperazin-2-yl]propyl]-3-methylpent-2-enamide Chemical compound OCCC(/C)=C/C(=O)N(O)CCCC1NC(=O)C(CCCN(O)C(=O)\C=C(/C)CCO)NC1=O MKDKGLNKTMDNHY-WXUKJITCSA-N 0.000 description 1
- VJDIYIXCDVYFOT-ADVDSDLCSA-N 5-[2-[3-[[(2r)-4-[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethylsulfanyl]-4-hydroxy-4-methyl-5-oxopentanoic acid Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C(C)(O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VJDIYIXCDVYFOT-ADVDSDLCSA-N 0.000 description 1
- QZQXRZXYWVQWAY-UHFFFAOYSA-N 8-(9h-fluoren-9-ylmethoxycarbonylamino)octanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCCCCCCC(=O)O)C3=CC=CC=C3C2=C1 QZQXRZXYWVQWAY-UHFFFAOYSA-N 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 235000005903 Dioscorea Nutrition 0.000 description 1
- 235000000504 Dioscorea villosa Nutrition 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- QCUYNKMUDZHGNK-UHFFFAOYSA-N Monascorubramine Natural products CCCCCCCC(=O)C1=C2C=C3C=C(NC=C3C(=O)C2(C)OC1=O)C=CC QCUYNKMUDZHGNK-UHFFFAOYSA-N 0.000 description 1
- IIPVSGPTPPURBD-UHFFFAOYSA-N Monascorubrin Natural products C1=C2C=C(C=CC)OC=C2C(=O)C2(C)C1=C(C(=O)CCCCCCC)C(=O)O2 IIPVSGPTPPURBD-UHFFFAOYSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940099246 mevacor Drugs 0.000 description 1
- IIPVSGPTPPURBD-HAOIVFDCSA-N monascorubrin Chemical compound C1=C2C=C(\C=C\C)OC=C2C(=O)[C@@]2(C)C1=C(C(=O)CCCCCCC)C(=O)O2 IIPVSGPTPPURBD-HAOIVFDCSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000001053 orange pigment Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- OVOAWDOEFJNCGI-UHFFFAOYSA-N rubropunctatamine Natural products CCCCCC(=O)C1=C2C=C3C=C(NC=C3C(=O)C2(C)OC1=O)C=CC OVOAWDOEFJNCGI-UHFFFAOYSA-N 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention discloses a composition for lowering blood lipid and elevating high-density lipoprotein and a method for manufacturing the same; thecomposition comprises monascin or ankaflavin, or a combination thereof; the manufacturing method comprises the steps of: treating a Monascus fermented product with acetone for three times; elevating the concentration of the Monascus fermented product by a process of decompress concentration; and extracting the monascin and the ankaflavin from the Monascus fermented product with a silicagel column chromatography, a Sephadex LH-20 column chromatography, the silica gel column chromatography, and a preparative high performance liquid chromatography sequentially. (Figure 1)
Description
Composition for Lowering Blood Lipid and Elevating
High-density Lipoprotein and Method for Manufacturing the
Same
1. Field of the Invention
The present invention relates to composition for lowering blood lipid and elevating high-density lipoprotein, and more particularly to a composition containing monascin or ankaflavin, or a combination thereof, for lowering blood lipid and elevating high-density lipoprotein. 2. Description of the Prior Art
The content of cholesterol in blood is closely related to the incidence of cardiovascular diseases. According to previous studies, dyslipidemia plays an important role in the cardiovascular diseases, thus the concentration of cholesterol in biood can be a well predictor for the cardiovascular diseases. When the concentration of serum cholesterol is more than 200 mg/dL, the probability of dying of coronary heart disease is raised rapidly. A person who has high content of cholesterol should have high morbidity rate of coronary heart disease and high death rate, but if the content of cholesterol is lowered by the treatment of a medical or a non-medical process, the incidence rate of the cardiovascular diseases caused by coronary sclerosis can be decreased significantly.
In recent years, health foods are developed vigorously, and multi-functional
Monascus fermented products are gradually paid attention. In Asia, the application of Monascus species in food and medicine has thousand years of history.
The important secondary metabolites of Monascus species include: (1) a group of pigments, including red pigments (rubropunctamine and monascorubramine), yellow pigments (ankaflavin and monascin) and orange pigments (rubropunctanin and monascorubrin); (2) cholesterol-lowering substance, such as monacolin K (also called as lovastatin, mevinolin and mevacor); (3) blood pressure lowering substance, such as y-aminobutyric acid (GABA); and (4) antioxidants, including dimerumic acid and 3-hydoxy-4-methoxy- benzoic acid.
In the above important secondary metabolites of Monascus species, owing to the monacolin K can reduce the activity of hydroxyl methylglutaryl-CoA reductase (HMG-CoA reductase), which is a key enzyme in the process of cholesterol biosynthesis, the monacolin K has a significantly effect for lowering cholesterol.
On the other hand, cholesterol in blood can be divided into two categories according to their density, including High Density Lipoprotein —Cholesterol (HDL-C) and Low Density Lipoprotein —Cholesterol (LDL-C). Many researches indicate that HDL-C is a kind of good cholesterol, and LDL-C is bad cholesterol.
High concentration of HDL-C and low concentration of LDL-C are helpful in decreasing the incidence of cardiovascular disease and atherosclerosis.
Owing to total cholesterol (TC) is composed of HDL-C, LDL-C, triglyceride (TG), and other lipoprotein cholesterols, the amount of HDL-C and LDL-C can be substantially increased in company with the elevation of the concentration of
TC. Most researches illustrate that after the concentration of TC being lowered by cholesterol-lowering drugs, the concentration of HDL-C is also decreased greatly. However, if the concentration of HDL-C can be maintained or elevated, the prevention of cardiovascular diseases can be achieved.
However, although the above-mentioned monacolin K has the effect of lowering cholesterol, the concentration of HDL-C can not be elevated by monacolin K, and the effect of preventing cardiovascular diseases and atherosclerosis by monacolin K is very limited.
In view of this, it is necessary to provide a novel composition and a method for manufacturing the same, wherein the composition has effects of lowering blood lipid and elevating the concentration of HDL-C simultaneously, so as to decrease the incidence of cardiovascular diseases and atherosclerosis effectively.
In view of the above shortcomings of the prior art, the inventors of the present invention resorted to past experience, imagination, and creativity, performed experiments and researches repeatedly, and eventually devised the present invention, a composition for lowering blood lipid and elevating high-density lipoprotein and a method for manufacturing the same,
The major objective of the present invention is to provide the composition for lowering blood lipid and elevating high-density lipoprotein, which comprises monascin and can lower the concentration of blood lipid and elevate the concentration of high-density lipoprotein effectively.
According to the above objective, the present invention provides a composition for lowering blood lipid and elevating high-density lipoprotein, wherein the composition comprises monascin, which is a Monascus yellow pigment and extracted from a Monascus fermented product.
Another objective of the present invention is to provide the method for manufacturing a composition for lowering blood lipid and elevating high-density lipoprotein, by a series of extraction processes, a composition containing monascin can be obtained, and the composition can lower the concentration of blood lipid and elevate the concentration of high-density lipoprotein effectively.
According to the above objective, the present invention provides a method for manufacturing a composition for lowering blood lipid and elevating high-density lipoprotein, wherein the method comprises the steps of: (1) providing a Monascus fermented product; (2) treating the Monascus fermented product with acetone for three times; (3) elevating the concentration of the product obtained from the previous step by a process of decompress concentration in a specific temperature range; (4) separating a pigment fraction from the product obtained from the previous step by a silica gel column chromatography; (5) separating a yellow pigment fraction from the pigment fraction by a Sephadex LH-20 column chromatography; (6) separating a fraction containing monascin and ankaflavin from the yellow pigment fraction by the silica gel column chromatography; and (7) separating monascin from the fraction containing monascin and ankaflavin obtained from the previous step by a preparative high performance liquid chromatography (pre-HPLC).
Further objective of the present invention is to provide the composition for lowering blood lipid and elevating high-density lipoprotein, which comprises ankaflavin and can lower the concentration of blood lipid and elevate the concentration of high-density lipoprotein effectively.
According to the above objective, the present invention provides a composition for lowering blood lipid and elevating high-density lipoprotein, wherein the composition comprises ankaflavin, which is a Monascus yellow pigment and extracted from a Monascus fermented product.
Further objective of the present invention is to provide the method for manufacturing a composition for lowering blood lipid and elevating high-density lipoprotein, by a series of extraction processes, a composition containing ankaflavin can be obtained, and the composition can lower the concentration of blood lipid and elevate the concentration of high-density lipoprotein effectively.
According to the above objective, the present invention provides a method for manufacturing a composition for lowering blood lipid and elevating high-density lipoprotein, wherein the method comprises the steps of: (1) providing a Monascus fermented product; (2) treating the Monascus fermented product with acetone for three times; (3) elevating the concentration of the product obtained from the previous step by a process of decompress concentration in a specific temperature range; (4) separating a pigment fraction from the product obtained from the previous step by a silica gel column chromatography; (5) separating a yellow pigment fraction from the pigment fraction by a Sephadex LH-20 column chromatography; (6) separating a fraction containing monascin and ankaflavin from the yellow pigment fraction by the silica gel column chromatography; and (7) separating ankaflavin from the fraction containing monascin and ankaflavin obtained from the previous step by a pre-HPLC.
Further objective of the present invention is to provide the composition for lowering blood lipid and elevating high-density lipoprotein, which comprises monascin and ankaflavin and can lower the concentration of blood lipid and elevate the concentration of high-density lipoprotein effectively.
According to the above objective, the present invention provides a composition for lowering blood lipid and elevating high-density lipoprotein, wherein the composition comprises monascin and ankaflavin, which are both Monascus yellow pigments and extracted from a Monascus fermented product.
Further objective of the present invention is to provide the method for manufacturing a composition for lowering blood lipid and elevating high-density lipoprotein, by a series of extraction processes, a composition containing monascin and ankaflavin can be obtained, and the composition can lower the concentration of blood lipid and elevate the concentration of high-density lipoprotein effectively.
According to the above objective, the present invention provides a method for manufacturing a composition for lowering blood lipid and elevating high-density lipoprotein, wherein the method comprises the steps of: (1) providing a Monascus fermented product; (2) treating the Monascus fermented product with acetone for three times; (3) elevating the concentration of the product obtained from the previous step by a process of decompress concentration in a specific temperature range; (4) separating a pigment fraction from the product obtained from the previous step by a silica gel column chromatography; (5) separating a yellow pigment fraction from the pigment fraction by a Sephadex LH-20 column chromatography; (6) separating a fraction containing monascin and ankaflavin from the yellow pigment fraction by the silica gel columm chromatography; (7) separating monascin and ankaflavin respectively from the fraction containing monascin and ankaflavin obtained from the previous step by a pre-HPLC; and (8) mixing the monascin and the ankaflavin according to a specific ratio.
For a complete understanding of the aspects, structures and techniques of the invention, reference should be made to the following detailed description and accompanying drawings wherein:
FIG. 1 is a flow chart diagram of a method for manufacturing a Monascus fermented product of the present invention;
FIG. 2 is a flow chart diagram of a method for manufacturing a composition for lowering blood lipid and elevating high-density lipoprotein according to a first preferred embodiment of the present invention;
FIG. 3 is a flow chart diagram of detailed steps of step 104 according to the first preferred embodiment of the present invention;
FIG. 4 is a flow chart diagram of detailed steps of step 105 according to the - first preferred embodiment of the present invention;
FIG. 5 is a flow chart diagram of detailed steps of step 106 according to the first preferred embodiment of the present invention;
FIG. 6 is a flow chart diagram of detailed steps of step 107 according to the first preferred embodiment of the present invention;
FIG. 7 is a flow chart diagram of a method for manufacturing a composition for lowering blood lipid and elevating high-density lipoprotein according to a second preferred embodiment of the present invention;
FIG. 8 is a flow chart diagram of detailed steps of step 207 according to the second preferred embodiment of the present invention;
FIG. 9 is a flow chart diagram of a method for manufacturing a composition for lowering blood lipid and elevating high-density lipoprotein according to a third preferred embodiment of the present invention;
FIG. 10 is a flow chart diagram of detailed steps of step 307 according to the third preferred embodiment of the present invention;
FIG. 11 is a diagram of quantitative results of a lipid plaque staining experiment; and
FIG. 12 is a comparative diagram for the effect of the inhibition of cholesterol by monascin, ankaflavin and monacolin K with the same concentration.
To achieve the foregoing objectives and effects, the inventors utilize a
Monascus fermented product as an extraction substrate, and extract the Monascus fermented product by a series of specific processes, under constant tests and regulations, thus achieving a composition for lowering blood lipid and elevating high-density lipoprotein and a method for manufacturing the same of the present invention. Hereinafter, the composition for lowering blood lipid and elevating high-density lipoprotein and the method for manufacturing the same according to a first, a second and a third preferred embodiment of the present invention are described in detail to illustrate the ingredients of the composition and the method for manufacturing the same of the present invention.
Before introducing the preferred embodiments of the present invention, the manufacturing method of a Monascus fermented product should be illustrated first. Referring to FIG. 1, which is a flow chart diagram of the method for manufacturing the Monascus fermented product of the present invention. The method comprises the steps of: (step 001) providing a substrate, which can be rice or dioscorea, wherein the water content of the substrate should be below 15%, and the optimal water content is 7%; (step 002) adding water to the substrate to make the ratio of the substrate to water be 1:0.5% ~ 1:1.5%, wherein the optimal ratio is 1:0.75%; (step 003) soaking the substrate in water, wherein the soaking time is 0~60 min, and the optimal time is 30 min; (step 004) sterilizing the substrate, wherein the sterilization condition is 121°C for 10~60 min; (step 005) cooling the substrate down to form a culture medium; (step 006) inoculating a specific Monascus spp. to the culture medium, wherein the specific
Monascus spp. can be Monascus purpureus; (step 007) culturing the culture medium inoculated with the specific Monascus spp., wherein the culture medium is cultured under a temperature of 25~37°C, a humidity of 50~80%, and for 8~20 days, and the optimal culture condition is the temperature of 30, the humidity of 60%, and for 10 days; (step 008) drying the Munascus fermented product cultured in the previous step to make the Munascus fermented product have a water content below 15%, wherein the optimal water content is 6%. By the above processes, the Monascus fermented product is manufactured.
In the method for manufacturing the Monascus fermented product of the present invention, the strains of Monascus purpureus can be selected from
Monascus purpureus NTU 568 or Monascus purpureus PAN 790.
Monascus purpureus NTU 568 is deposited in Agricultural Research Culture
Collection (NRRL) in November 13, 2009, and the given accession number is
NRRL 50338. The characteristics of Monascus purpureus NTU 568 includes rapid growth, strong ability of starch hydrolysis, and strong ability of metabolites production. The basic culture manner of Monascus purpureus NTU 568 is to be cultured with a medium containing 2% of rice powder, the best culture temperature is 30°C, the best culture time is 48 hours, the best culture pressure is latm, and the growth of Monascus purpureus NTU 568 is oxygen dependent.
Monascus purpureus PAN 790 is deposited in Agricultural Research Culture
Collection (NRRL) in November 13, 2009, and the given accession number is
NRRL 50337. The characteristics of Monascus purpureus PAN 790 includes slow growth, being able to produce large amount of monacolin K, and being mutated in and cloned from red mold rice. The culture medium for Monascus purpureus PAN 790 includes 2% of rice powder; the culture temperature is 30°C; the culture time is 48 hours; the culture pressure is 1 atm; the sterilization manner for Monascus purpureus PAN 790 is 121°C for 20 min; the pH value before sterilization is 5; the growth of Monascus purpureus PAN 790 is oxygen dependent; and the storage temperature for Monascus purpureus PAN 790 is 4°C.
Subsequently, the first preferred embodiment of the present invention is described in detail. The composition for lowering blood lipid and elevating high-density lipoprotein according to the first preferred embodiment of the present invention contains monascin, which is a Monascus yellow pigment, and extracted from the above-mentioned Monascus fermented product. Wherein an amount of the monascin taken by an adult is more than 2.4 mg per day, so that the concentration of blood lipid can be lowered and the concentration of the high-density lipoprotein in blood can be elevated effectively.
Referring to Fig. 2, which is a flow chart diagram of a method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to the first preferred embodiment of the present invention. The method includes the steps of: (step 101) providing the
Monascus fermented product; (step 102) treating the Monascus fermented product with acetone for three times, wherein the ratio of the Monascus fermented product to the acetone is 1:10 ~ 1:50; (step 103) elevating the concentration of the product obtained from the previous step by a process of decompress concentration in a specific temperature range, wherein the specific temperature range is 40°C ~ 60°C; (step 104) separating a pigment fraction from the product obtained from the previous step by a silica gel column chromatography; (step 105) separating a yellow pigment fraction from the pigment fraction by a Sephadex LH-20 column chromatography; (step 106) separating a fraction containing monascin and ankaflavin from the yellow pigment fraction by the silica gel column chromatography; and (step 107)
separating monascin from the fraction containing monascin and ankaflavin obtained from the previous step by a preparative high performance liquid chromatography (pre-HPLC).
Referring to Fig. 3, which is a flow chart diagram of detailed steps of step 104 according to the first preferred embodiment of the present invention. The above step 104 can be subdivided into the following steps of: (step 104a) adding the product obtained from step 103 to a silica gel column; (step 104b) adding a plurality of washing solutions to the silica gel column sequentially, wherein the plurality of washing solutions are Hexane, Hexane : Ethanol = 9:1, Hexane :
Ethanol = 8:2, Hexane :Ethanol = 7:3, Hexane : Ethanol = 1:1, and Ethanol sequentially; (step 104c) collecting 12~15 fractions flowing out from the silica gel column, wherein the time period of each fraction flowing out from the silica gel column is 5~10 min; (step 104d) analyzing the fractions collected in the previous step by a high performance liquid chromatography (HPLC) in combination with a photodiode-array (PDA), and collecting fractions containing monascin and ankaflavin; and (step 104€) mixing the fractions collected in the previous step to form the pigment fraction.
Referring to Fig. 4, which is a flow chart diagram of detailed steps of step 105 according to the first preferred embodiment of the present invention. The above step 105 can be subdivided into the following steps of: (step 105a) adding the pigment fraction obtained from step 104 to a Sephadex LH-20 column; (step 105b) adding a washing solution to the Sephadex LH-20 column, wherein the washing solution is Methanol : Acetonitrile = 9:1; (step 105¢) collecting 3~5 fractions flowing out from the Sephadex LLH-20 column, wherein the time period of each fraction flowing out from the silica gel column is 5~10 min; (step 105d) analyzing the fractions collected in the previous step by a HPLC-PDA, and collecting fractions containing monascin and ankaflavin; and (step 105¢) mixing the fractions collected in the previous step to form the yellow pigment fraction.
Referring to Fig. 5, which is a flow chart diagram of detailed steps of step 106 according to the first preferred embodiment of the present invention. The above step 106 can be subdivided into the following steps of: (step 106a) adding the yellow pigment fraction obtained from step 105 to a silica gel column; (step 106b) adding a plurality of washing solutions to the silica gel column sequentially, wherein the plurality of washing solutions are Dichloromethane :
Ethanol = 95:5, Dichloromethane : Ethanol = 9:1, and Dichloromethane : Ethanol = 4:1 sequentially; (step 106c) collecting 3~5 fractions flowing out from the silica gel column, wherein the time period of each fraction flowing out from the silica gel column is 5~10 min; (step 106d) analyzing the fractions collected in the previous step by a HPLC-PDA, and collecting fractions containing monascin and ankaflavin; and (step 106¢) mixing the fractions collected in the previous step to form the fraction containing monascin and ankaflavin.
Referring to Fig. 6, which is a flow chart diagram of detailed steps of step 107 according to the first preferred embodiment of the present invention. The above step 107 can be subdivided into the following steps of: (step 107a) washing and separating the fraction containing monascin and ankaflavin obtained from step 106 by a Cig column in combination with a HPLC and a washing solution, wherein the washing solution is Methanol : water = 85:15; (step 107b) collecting 2 fractions flowing out from the C3 column, wherein the time period of each fraction flowing out from the silica gel column is 5~10 min; and (step 107¢) analyzing the fractions collected in the previous step by a HPLC-PDA, and collecting fractions containing monascin.
In the above steps 104d, 105d and 106d, the column applied in the HPLC process is C18 column (25 cm * 4.6 mm, id. = 5um), the mobile phase is
Acetonitrile : water : trifluoroacetate = 62:38:0.05, the speed of flow is 1 mL/min, and the UV absorption amount under 231 nm is detected with a multiwavelength detector (because of the curves of monascin and ankaflavin have peaks under 231 nm). Furthermore, standards of monascin and ankaflavin should be applied as comparison groups for comparing the peaks with the ones of analytes, so as to determine whether the analytes are monascin and ankaflavin or not.
Additionally, in the above-mentioned step 107c, the analysis conditions of
HPLC process are almost the same as step 104d, step 105d and step 106d.
However, the special aspect of step 107c is that monascin and ankaflavin are separated from each other by the property of polarity difference. Owing to the
Cis column can wash out the more polar ingredients at earlier time point, and monascin is more polar relative to ankaflavin, monascin can be washed out from
Cis column earlier than ankaflavin. By this property, monascin can be collected in the fractions washed out at earlier time point, and monascin in the fractions can be identified by comparing the washing time and the absorption wavelength with the monascin standard.
Subsequently, the second preferred embodiment of the present invention is described in detail. The composition for lowering blood lipid and elevating high-density lipoprotein according to the second preferred embodiment of the present invention contains ankaflavin, which is a Monascus yellow pigment, and extracted from the above-mentioned Monascus fermented product. Wherein an amount of the ankaflavin taken by an adult is more than 0.6 mg per day, so that the concentration of blood lipid can be lowered and the concentration of the high-density lipoprotein in blood can be elevated effectively.
Referring to Fig. 7, which is a flow chart diagram of a method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to the second preferred embodiment of the present invention. Steps 201~206 of the second preferred embodiment are almost the same as the steps 101~106, and thus the steps 201~206 will not be described again here. The difference between the second preferred embodiment and the first preferred embodiment is that step 207 of the second preferred embodiment separates ankaflavin by the pre-HPLC process.
Referring to Fig. 8, which a flow chart diagram of detailed steps of step 207 according to the second preferred embodiment of the present invention. The above step 207 can be subdivided into the following steps of: (step 207a) washing and separating the fraction containing monascin and ankaflavin obtained from step 206 by a Cig column in combination with a HPLC and a washing solution, wherein the washing solution in step (7.1) is Methanol : water = 85:15; (Step 207b) collecting 2 fractions flowing out from the C;3 column, wherein the time period of each fraction flowing out from the silica gel column is 5~10 min; and (step 207c) analyzing the fractions collected in the previous step by a
HPLC-PDA, and collecting fractions containing ankaflavin.
In the above-mentioned step 207c, monascin and ankaflavin are separated from each other by the property of polarity difference. Owing to the Cg column can wash out the more polar ingredients at earlier time point, and monascin is more polar relative to ankaflavin, monascin can be washed out from Cy; column earlier than ankaflavin. By this property, ankaflavin can be collected in the fractions washed out at later time point, and ankaflavin in the fractions can be identified by comparing the washing time and the absorption wavelength with the ankaflavin standard.
Subsequently, the third preferred embodiment of the present invention is described in detail. The composition for lowering blood lipid and elevating high-density lipoprotein according to the third preferred embodiment of the present invention contains monascin and ankaflavin, which are both Monascus yellow pigments, and extracted from the above-mentioned Monascus fermented product. Wherein the content ratio of the monascin to the ankaflavin is in a range from 1:1 to 10:1, and the optimum content ratio of the monascin to the ankaflavin is 3.56:1. Furthermore, an amount of the monascin taken by an adult is more than 2.4 mg per day, and an amount of the ankaflavin taken by an adult is more than 0.6 mg per day, so that the concentration of blood lipid can be lowered and the concentration of the high-density lipoprotein in blood can be elevated effectively.
Referring to Fig. 9, which is a flow chart diagram of a method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to the third preferred embodiment of the present invention. Steps 301~306 of the third preferred embodiment are almost the same as the steps 101~106 and 201~206, and thus the steps 301~306 will not be described again here. The difference between the third preferred embodiment and the first preferred embodiment (or second preferred embodiment) is that step 307 of the third preferred embodiment separates monascin and ankaflavin by the pre-HPLC process. Eventually, according to step 308, mixing monascin and ankaflavin together according to a specific ratio, wherein the specific ratio is in a range from 1:1 to 10:1, and the optimum value of the specific ratio is 3.56:1.
Referring to Fig. 10, which is a flow chart diagram of detailed steps of step 307 according to the third preferred embodiment of the present invention. The above step 307 can be subdivided into the following steps of: (step 307a) washing and separating the fraction containing monascin and ankaflavin obtained from step 306 by a Cs column in combination with a HPLC and a washing solution, wherein the washing solution is Methanol : water = 85:15; (step 307b) collecting 2 fractions flowing out from the C;g column, wherein the time period of each fraction flowing out from the C3 column is about 5~10 min; and (step 307c) analyzing the fractions collected in the previous step by a HPLC-PDA, and collecting fractions containing monascin and ankaflavin respectively.
In the above-mentioned step 307c, monascin and ankaflavin are separated from each other by the property of polarity difference. Owing to the C;5 column can wash out the more polar ingredients at earlier time point, and monascin is more polar relative to ankaflavin, monascin can be washed out from C3 column earlier than ankaflavin. By this property, monascin can be collected in the fractions washed out at earlier time point, and ankaflavin can be collected in the fractions washed out at later time point. Furthermore, monascin and ankaflavin in the fractions can be identified by comparing the washing time and the absorption wavelength with the monascin and ankaflavin standards.
In order to prove that the compositions of the first, the second and the third preferred embodiments indeed have the effect of lowering blood lipid and elevating high-density lipoprotein, the compositions are analyzed and compared for their functions by several experiments as followings. Hereinafter, the composition of the first preferred embodiment is called as monascin (MS for abbreviation), and the amount of the monascin taken by an experimental animal is equivalent to 9.82 mg taken by an adult human per day; the composition of the second preferred embodiment is called as ankaflavin (AF for abbreviation), and the amount of the ankaflavin taken by an experimental animal is equivalent to 1.43 mg taken by an adult human per day; the composition of the third preferred embodiment is called as monascin + ankaflavin (MS+AF for abbreviation), and the amount of the monascin and ankaflavin taken by an experimental animal are equivalent to 9.82 mg and 1.43 mg taken by an adult human per day respectively.
Additionally, a composition containing monacolin K is utilized as a comparison group, which is called as MK for abbreviation.
Firstly, the experiment utilizes hamsters feed with high cholesterol diet as experimental animals, which are then feed with MS, AF, MS+AF, and MK for 8 weeks, and then each of cholesterol parameters in blood of the hamsters are analyzed. The cholesterol parameters include total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), ratio of LDL-C to HDL-C, and malondialdehyde (MDA).
The amount of the MK taken by the experimental animals is equivalent to 2.89 mg taken by an adult human per day. Additionally, a normal diet group is referred to as NOR, and a high cholesterol diet group is referred to as HC.
Referring to the following table 1 and table 2, wherein the table 1 illustrates the results of the above-mentioned animal experiments, and the table 2 illustrates the reducing rate or the increasing rate of MS, AF, MS+AF, and MK relative to
HC. In the results of the reducing rate of TC, the groups of MS and AF both can lower the amount of TC in serum significantly, and the effect of MS and AF are better than that of MK; the group of MS+AF has the effect of lowering the amount of TC better than the other groups. In the results of the reducing rate of
TG, groups of MS, AF and MK+AF can lower the amount of TG in serum significantly, and the effect of MS, AF and MS+AF are better than that of MK. In the results of the increasing rate of HDL-C, the groups of MS and AF both can increase the amount of TC in serum significantly, and the effect of MS and AF are better than that of MK; the group of MS+AF has the effect of increasing the amount of HDL-C better than the other groups. In the results of the reducing rate of LDL-C, although the group of MS has the effect almost the same as MK, the groups of AF and MS+AF have the effect of lowering the amount of LDL-C better than the MK group. In the results of the reducing rate of LDL/HDL, the effect of MS group is better than MK group, and the effects of AF and MS+AF are better than the other groups, thus monascin, ankaflavin and monascintankaflavin is more contributive to ameliorate the occurrence of cardiovascular diseases and atherosclerosis than monacolin K. In the results of the reducing rate of MDA, the groups of MS, AF and MS+AF can lower the amount of MDA in serum significantly, and the effects of the groups of MS, AF and MS+AF are all better than the MK group.
Table 1
HDL-C LDL-C MDA
Grou TC content 1G content content content LDL/HDL content
P (mg/dL) (mg/dL) (mg/dL) (mg/dL) (mg/dL) 111.8 168.8 66.6 19.9 0.278 8.93
NOR
+10.7 +35.6 +5.97 +2.59 +0.038 +1.79 236.5 226.3 08.1 68.3 0.569 11.80
HC
+18.9 176.5 +8.89 +9.75 +0.093 +1.85 190.3 131.1 96.9 45.0 0.489 10.37
MK
+25.1 +36.7 +8.84 £6.97 +0.050 +1.73 165.8 82.8 114.2 45.1 0.416 8.62
MS
+10.6 +9.0 £9.36 +3.36 +0.022 +1.45 168.9 94.5 118.6 394 0.355 9.07
AF
+11.5 +18.0 +8.09 +5.80 +0.049 +1.45 160.3 85.6 125.7 38.5 0.351 8.45
MS+AF +7.6 £10.60 +7.30 +3.10 +0.051 +1.23
Table 2
TC TG HDL-C LDL-C LDL/HDL MDA group reducing | reducing | increasing | reducing | reducing rate | reducing rate (%) rate (%) rate (%) rate (%) (%) rate (%)
Another important indicator for evaluating atherosclerosis is the analysis of lipid plaque staining in arteries, and the results of lipid plaque staining can indicate that whether lipid plaque deposits on arterial vascular walls. Large amounts of lipid with over-oxidation can cause bulk deposition of foam cells, and then the vascular walls lose elasticity and large amounts of lipid plaque are deposited, so as to lead to atherosclerosis. Referring to Fig. 11, which is a diagram of quantitative results of the lipid plaque staining experiment. The results demonstrate that high cholesterol diet (HC group) for eight weeks may cause the experimental animals to deposit large amounts of lipid plaque on arterial vascular walls in the thoracic cavity, but the deposition of lipid plaque in the NOR group is less than HC group. Although the MK group (the amount of the MK taken is 2.89 mg taken by an adult human per day) can lower the amount of lipid plaque, the effect of the MK group is not as good as that of the MS (the amount of the MS taken is 9.82 mg taken by an adult human per day), AF (the amount of the AF taken is 1.43 mg taken by an adult human per day) and
MS+AF groups (the content ratio of the monascin to the ankaflavin is 3.56:1); the effect of the AF group is better than that of the MS group, and the effect of the MS+AF group is better than that of the AF group.
In order to compare the inhibitory effect of cholesterol biosynthesis by monascin, ankaflavin and monacolin K, the present invention applies a cell experiment and treats cells with monascin, ankaflavin and monacolin K with the same concentration (100 ppb) for researching the influence of these ingredients on the cholesterol biosynthesis. Referring to Fig. 12, which is a comparative diagram for the effect of the inhibition of cholesterol by monascin, ankaflavin and monacolin K with the same concentration. The results demonstrate that ankaflavin has the best effect of inhibiting the biosynthesis of cholesterol, followed by monascin, and monacolin K has the weakest effect. These results are consistent with the above animal experiments, that is ankaflavin and monascin have better effect on blood lipid lowering than monacolin K.
It can be known from the above experiments that monascin, ankaflavin and monascintankaflavin can reduce TC, TG, LDL-C, MDA, and lipid plaque significantly, and can elevate the content of HDL-C in serum; additionally, the effect of monascin+ankaflavin is more prominent than the effect of monascin or ankaflavin. Thus, the compositions according to the first, second and third preferred embodiments not only can reduce the content of cholesterol in serum, but also can elevate the concentration of HDL-C in serum, so as to have extreme contribution to lower the incidence of cardiovascular diseases and atherosclerosis.
By the detailed description of the overall structure and technical content of the present invention, the following advantages of the present invention can be derived: 1. Each of the compositions provided by the present invention all have the effect of lowering blood lipid and elevating high-density lipoprotein, thus these compositions can be utilized to prevent and treat cardiovascular diseases and atherosclerosis.
2. Through the manufacturing method provided by the present invention, each of the compositions with high purity of the present invention can be extracted, and can be applied to lower the incidence of cardiovascular diseases and atherosclerosis. 3. Each of the compositions of the present invention are extracted from
Monascus fermented product, not synthesized artificially, thus the compositions can be regarded as natural food supplements, which not only can reduce the incidence of cardiovascular diseases and atherosclerosis, but also can avoid the production of side effects.
It should be understood that the embodiments of the present invention described herein are merely illustrative of the technical concepts and features of the present invention and are not meant to limit the scope of the invention. Those skilled in the art, after reading the present disclosure, will know how to practice the invention. Various variations or modifications can be made without departing from the spirit of the invention. All such equivalent variations and modifications are intended to be included within the scope of the invention.
As a result of continued thinking about the invention and modifications, the inventors finally work out the designs of the present invention that has many advantages as described above. The present invention meets the requirements for an invention patent, and the application for a patent is duly filed accordingly. It is expected that the invention could be examined at an early date and granted so as to protect the rights of the inventors.
Claims (43)
1. A composition for lowering blood lipid and elevating high-density lipoprotein, wherein the composition comprises monascin, which is a Monascus yellow pigment and extracted from a Monascus fermented product.
2. The composition for lowering blood lipid and elevating high-density lipoprotein according to claim 1, wherein an amount of the monascin taken by an adult is more than 2.4 mg per day.
3. A method for manufacturing a composition for lowering blood lipid and elevating high-density lipoprotein, wherein the method comprises the steps of: (1) providing a Monascus fermented product; (2) treating the Monascus fermented product with acetone for three times; (3) elevating the concentration of the product obtained from the previous step by a process of decompress concentration in a specific temperature range; (4) separating a pigment fraction from the product obtained from the previous step by a silica gel column chromatography; (5) separating a yellow pigment fraction from the pigment fraction by a Sephadex LH-20 column chromatography; (6) separating a fraction containing monascin and ankaflavin from the yellow pigment fraction by the silica gel column chromatography; and (7) separating monascin from the fraction containing monascin and ankaflavin obtained from the previous step by a preparative high performance liquid chromatography (pre-HPLC).
4, The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 3, wherein the ratio of the Monascus fermented product to the acetone in step (2) is 1:10 ~ 1:50.
5. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 3, wherein the specific temperature range in step (3) is 40°C ~ 60°C.
6. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 3, wherein the step (4) further comprises the steps of:
(4.1) adding the product obtained from step (3) to a silica gel column;
(4.2) adding a plurality of washing solutions to the silica gel column sequentially;
(4.3) collecting 12~15 fractions flowing out from the silica gel column;
(4.4) analyzing the fractions collected in the previous step by a high performance liquid chromatography (HPLC) in combination with a photodiode-array (PDA), and collecting fractions containing monascin and ankaflavin; and
(4.5) mixing the fractions collected in the previous step to form the pigment fraction.
7. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 6, wherein the plurality of washing solutions in step (4.2) are Hexane, Hexane : Ethanol = 9:1, Hexane : Ethanol = 8:2, Hexane :Ethanol = 7:3, Hexane : Ethanol = 1:1, and Ethanol sequentially.
8. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 3, wherein the step (5) further comprises the steps of:
(5.1) adding the pigment fraction obtained from step (4) to a Sephadex LH-20 column;
(5.2) adding a washing solution to the Sephadex LH-20 column;
(5.3) collecting 3~5 fractions flowing out from the Sephadex LH-20 column;
(5.4) analyzing the fractions collected in the previous step by a HPLC-PDA, and collecting fractions containing monascin and ankaflavin; and
(5.5) mixing the fractions collected in the previous step to form the yellow pigment fraction.
9. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 8, wherein the washing solution in step (5.2) is Methanol : Acetonitrile = 9:1.
10. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 3, wherein the step (6) further comprises the steps of:
(6.1) adding the yellow pigment fraction obtained from step (5) to a silica gel column;
(6.2) adding a plurality of washing solutions to the silica gel column sequentially;
(6.3) collecting 3~5 fractions flowing out from the silica gel column;
(6.4) analyzing the fractions collected in the previous step by a HPLC-PDA, and collecting fractions containing monascin and ankaflavin; and
(6.5) mixing the fractions collected in the previous step to form the fraction containing monascin and ankaflavin.
11. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 10, wherein the plurality of washing solutions in step (6.2) are Dichloromethane : Ethanol = 95:5, Dichloromethane : Ethanol = 9:1, and Dichloromethane : Ethanol = 4:1 sequentially.
12. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 3, wherein the step (7) further comprises the steps of:
(7.1) washing and separating the fraction containing monascin and ankaflavin obtained from step (6) by a C3 column in combination with a HPLC and a washing solution;
(7.2) collecting 2 fractions flowing out from the C;g column; and
(7.3) analyzing the fractions collected in the previous step by a HPLC-PDA, and collecting fractions containing monascin.,
13. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 12, wherein the washing solution in step (7.1) is Methanol : water = 85:15.
14. A composition for lowering blood lipid and elevating high-density lipoprotein, wherein the composition comprises ankaflavin, which is a Monascus yellow pigment and extracted from a Monascus fermented product.
15.The composition for lowering blood lipid and elevating high-density lipoprotein according to claim 14, wherein an amount of the ankaflavin taken by an adult is more than 0.6 mg per day.
16.A method for manufacturing a composition for lowering blood lipid and elevating high-density lipoprotein, wherein the method comprises the steps of! (1) providing a Monascus fermented product; (2) treating the Monascus fermented product with acetone for three times; (3) elevating the concentration of the product obtained from the previous step by a process of decompress concentration in a specific temperature range; (4) separating a pigment fraction from the product obtained from the previous step by a silica gel column chromatography; (5) separating a yellow pigment fraction from the pigment fraction by a Sephadex LH-20 column chromatography; (6) separating a fraction containing monascin and ankaflavin from the yellow pigment fraction by the silica gel column chromatography; and (7) separating ankaflavin from the fraction containing monascin and ankaflavin obtained from the previous step by a pre-HPLC.
17. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 16, wherein the ratio of the Monascus fermented product to the acetone in step (2) is 1:10 ~ 1:50.
18. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 16, wherein the specific temperature range in step (3) is 40°C ~ 60°C.
19. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 16, wherein the step (4) further comprises the steps of:
(4.1) adding the product obtained from step (3) to a silica gel column;
(4.2) adding a plurality of washing solutions to the silica gel column sequentially;
(4.3) collecting 12~15 fractions flowing out from the silica gel column;
(4.4) analyzing the fractions collected in the previous step by a HPLC-PDA, and collecting fractions containing monascin and ankaflavin; and
(4.5) mixing the fractions collected in the previous step to form the pigment fraction.
20. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 19, wherein the plurality of washing solutions in step (4.2) are Hexane, Hexane : Ethanol = 9:1, Hexane : Ethanol = 8:2, Hexane :Ethanol = 7:3, Hexane : Ethanol = 1:1, and Ethanol sequentially.
21. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 16, wherein the step (5) further comprises the steps of:
(5.1) adding the pigment fraction obtained from step (4) to a Sephadex LH-20 column;
(5.2) adding a washing solution to the Sephadex LH-20 column;
(5.3) collecting 3~5 fractions flowing out from the Sephadex LH-20 column;
(5.4) analyzing the fractions collected in the previous step by a HPLC-PDA, and collecting fractions containing monascin and ankaflavin; and
(5.5) mixing the fractions collected in the previous step to form the yellow pigment fraction.
22. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 21, wherein the washing solution in step (5.2) is Methanol : Acetonitrile = 9:1.
23. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 16, wherein the step (6) further comprises the steps of:
(6.1) adding the yellow pigment fraction obtained from step (5) to a silica gel column;
(6.2) adding a plurality of washing solutions to the silica gel column sequentially;
(6.3) collecting 3~5 fractions flowing out from the silica gel column;
(6.4) analyzing the fractions collected in the previous step by a HPLC-PDA, and collecting fractions containing monascin and ankaflavin; and
(6.5) mixing the fractions collected in the previous step to form the fraction containing monascin and ankaflavin.
24. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 23, wherein the plurality of washing solutions in step (6.2) are Dichloromethane : Ethanol = 95:5, Dichloromethane : Ethanol = 9:1, and Dichloromethane ; Fthanol = 4:1 sequentially.
25. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 16, wherein the step (7) further comprises the steps of:
(7.1) washing and separating the fraction containing monascin and ankaflavin obtained from step (6) by a C3 column in combination with a HPLC and a washing solution;
(7.2) collecting 2 fractions flowing out from the C,3 column; and
(7.3) analyzing the fractions collected in the previous step by a HPLC-PDA, and collecting fractions containing ankaflavin,
26. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 25, wherein the washing solution in step (7.1) is Methanol : water = 85:15.
27. A composition for lowering blood lipid and elevating high-density lipoprotein, wherein the composition comprises monascin and ankaflavin, which are both Monascus yellow pigments and extracted from a Monascus fermented product.28
28. The composition for lowering blood lipid and elevating high-density lipoprotein according to claim 27, wherein the content ratio of the monascin to the ankaflavin is in a range from 1:1 to 10:1.
29. The composition for lowering blood lipid and elevating high-density lipoprotein according to claim 27, wherein the optimum content ratio of the monascin to the ankaflavin is 3.56:1.
30.The composition for lowering blood lipid and elevating high-density lipoprotein according to claim 27, wherein an amount of the monascin taken by an adult is more than 2.4 mg per day, and wherein an amount of the ankaflavin taken by the adult is more than 0.6 mg per day.
31. A method for manufacturing a composition for lowering blood lipid and elevating high-density lipoprotein, wherein the method comprises the steps of: (1) providing a Monascus fermented product; (2) treating the Monascus fermented product with acetone for three times; (3) elevating the concentration of the product obtained from the previous step by a process of decompress concentration in a specific temperature range; (4) separating a pigment fraction from the product obtained from the previous step by a silica gel column chromatography; (5) separating a yellow pigment fraction from the pigment fraction by a Sephadex LH-20 column chromatography; (6) separating a fraction containing monascin and ankaflavin from the yellow pigment fraction by the silica gel column chromatography; (7) separating monascin and ankaflavin respectively from the fraction containing monascin and ankaflavin obtained from the previous step by a pre-HPLC; and (8) mixing the monascin and the ankaflavin according to a specific ratio.
32. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 31, wherein the ratio of the Monascus fermented product to the acetone in step (2) is 1:10 ~ 1:50.
33. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 31, wherein the specific temperature range in step (3) is 40°C ~ 60°C.
34. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 31, wherein the step (4) further comprises the steps of:
(4.1) adding the product obtained from step (3) to a silica gel column;
(4.2) adding a plurality of washing solutions to the silica gel column sequentially;
(4.3) collecting 12~15 fractions flowing out from the silica gel column;
(4.4) analyzing the fractions collected in the previous step by a HPLC-PDA, and collecting fractions containing monascin and ankaflavin; and
(4.5) mixing the fractions collected in the previous step to form the pigment fraction.
35. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 34, wherein the plurality of washing solutions in step (4.2) are Hexane, Hexane : Ethanol = 9:1, Hexane : Ethanol = 8:2, Hexane :Ethanol = 7:3, Hexane : Ethanol = 1:1, and Ethanol sequentially.
36. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 31, wherein the step (5)
further comprises the steps of:
(5.1) adding the pigment fraction obtained from step (4) to a Sephadex LH-20 column;
(5.2) adding a washing solution to the Sephadex LH-20 column;
(5.3) collecting 3~5 fractions flowing out from the Sephadex LH-20 column;
(5.4) analyzing the fractions collected in the previous step by a HPLC-PDA, and collecting fractions containing monascin and ankaflavin; and
(5.5) mixing the fractions collected in the previous step to form the yellow pigment fraction.
37. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 36, wherein the washing solution in step (5.2) is Methanol : Acetonitrile = 9:1.
38. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 31, wherein the step (6) further comprises the steps of:
(6.1) adding the yellow pigment fraction obtained from step (5) to a silica gel column;
(6.2) adding a plurality of washing solutions to the silica gel column sequentially;
(6.3) collecting 3~5 fractions flowing out from the silica gel column;
(6.4) analyzing the fractions collected in the previous step by a HPLC-PDA, and collecting fractions containing monascin and ankaflavin; and
(6.5) mixing the fractions collected in the previous step to form the fraction containing monascin and ankaflavin.
39. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 38, wherein the plurality of washing solutions in step (6.2) are Dichloromethane : Ethanol = 95:5, Dichloromethane : Ethanol = 9:1, and Dichloromethane : Ethanol = 4:1 sequentially.
40. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 31, wherein the step (7) further comprises the steps of:
(7.1) washing and separating the fraction containing monascin and ankaflavin obtained from step (6) by a Cg column in combination with a HPLC and a washing solution;
(7.2) collecting 2 fractions flowing out from the Cz column; and
(7.3) analyzing the fractions collected in the previous step by a HPLC-PDA, and collecting fractions containing monascin and ankaflavin respectively.
41. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 40, wherein the washing solution in step (7.1) is Methanol : water = 85:15.
42. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 31, wherein the specific ratio in step (8) is in a range from 1:1 to 10:1.
43. The method for manufacturing the composition for lowering blood lipid and elevating high-density lipoprotein according to claim 31, wherein the optimum value of the specific ratio in step (8) is 3.56:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG2011058302A SG187997A1 (en) | 2011-08-12 | 2011-08-12 | Composition for lowering blood lipid and elevating high-density lipoprotein and method for manufacturing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG2011058302A SG187997A1 (en) | 2011-08-12 | 2011-08-12 | Composition for lowering blood lipid and elevating high-density lipoprotein and method for manufacturing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG187997A1 true SG187997A1 (en) | 2013-03-28 |
Family
ID=48014626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2011058302A SG187997A1 (en) | 2011-08-12 | 2011-08-12 | Composition for lowering blood lipid and elevating high-density lipoprotein and method for manufacturing the same |
Country Status (1)
| Country | Link |
|---|---|
| SG (1) | SG187997A1 (en) |
-
2011
- 2011-08-12 SG SG2011058302A patent/SG187997A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6016895B2 (en) | A novel strain of microalgae producing squalene | |
| Huang et al. | Effects of rutin and its derivatives on citrinin production by Monascus aurantiacus Li AS3. 4384 in liquid fermentation using different types of media | |
| CN103224890A (en) | Monascus ruber for high generation of lovastatin and gamma-aminobutyric acid and low generation of pigment, use thereof, and functional Monascus sp. prepared through using Monascus ruber | |
| KR102084003B1 (en) | Method for preparing nucleotides of lactic acid bacteria inclusion-complexed with low-molecular functional biomaterial and Cubisome prepared thereby | |
| CN102199565B (en) | Enterococcus faecium and method for producing equol by using Enterococcus faecium and application of Enterococcus faecium | |
| Zhang et al. | Effect of arginine supplementation on Monacolin K yield of Monascus purpureus | |
| Aguilar-Zárate et al. | On-line monitoring of Aspergillus niger GH1 growth in a bioprocess for the production of ellagic acid and ellagitannase by solid-state fermentation | |
| KR101167345B1 (en) | Mutant yeast, method of producing glutathione-rich yeast, culture thereof, fraction thereof, yeast extract and glutathione-containing foods and drinks | |
| US9364457B2 (en) | Method for manufacturing composition for lowering blood lipid and elevating high-density lipoprotein | |
| KR101980450B1 (en) | Composition of active wild-cultivated ginseng having increased ginsenoside Rd and compound K, chlorgenic acid and quercetin, and preparation method thereof | |
| CN103911407B (en) | The preparation method of the Azaphilone class dimer compound in a kind of marine fungi source and application | |
| CN103880826B (en) | A kind of isobenzofuran ketonic compound and its preparation method and application | |
| TW202102244A (en) | Plant fermented product and uses thereof for protecting liver, improving mitochondrial activity of cells, anti-oxidation, anti-aging, and increasing expression of cct gene, pink1 gene, mrps5 gene, foxo gene and ubl5 gene | |
| EP2559433B1 (en) | Method for manufacturing a composition for lowering blood lipid and elevating high-density lipoprotein. | |
| CA2826966C (en) | Composition for lowering blood lipid and elevating high-density lipoprotein and method for manufacturing the same | |
| CN102286565B (en) | Preparation method of theaflavin monomer | |
| SG187997A1 (en) | Composition for lowering blood lipid and elevating high-density lipoprotein and method for manufacturing the same | |
| CN102908343B (en) | Can reducing blood lipid and promote composition and the manufacture method of HDL-C | |
| KR101420904B1 (en) | Composition for Lowering Blood Lipid and Elevating High-density Lipoprotein and Method for Manufacturing the Same | |
| TWI415619B (en) | Composition for lowering blood lipid and elevating high-density lipoprotein and a method for manufacturing the same | |
| CN101955455B (en) | Method for processing sample of natural beta-carotene or lycopene fermentation liquor produced by fermenting blakeslea trispora | |
| CN111500657B (en) | Method for co-producing hypocrellin A and tabasheer exopolysaccharide | |
| JP2013063925A (en) | Mixture capable of reducing blood lipid and raising hdl cholesterol, and method for producing the same | |
| CN108299274A (en) | A kind of natural indoles, preparation method and application | |
| JP7330575B2 (en) | Use of monascinol in the preparation of fat-reduced products |